ReviewInternational journal of molecular sciences2023
Chronic Kidney Disease as a Comorbidity in Heart Failure.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed.
- Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics and the Pharmacokinetics of Balcinrenone When Dosed with a P-gp Inhibitor.Journal of clinical pharmacology · 2026Trial
- Outcomes of Bolus Dose Furosemide Versus Continuous Infusion in Patients With Acute Decompensated Left Ventricular Failure and Atrial Fibrillation.Clinical cardiology · 2024Trial
- Predictors of mortality among non-traumatic critically ill patients with electrolyte imbalances attending a Ugandan regional referral hospital Emergency Department.African journal of emergency medicine : Revue africaine de la medecine d'urgence · 2026Article
- Risk Factors for Cardiovascular Disease: Epidemiology, Screening, Prevention, and Therapeutic Interventions.MedComm · 2026Review
- The Inflammaging-Redox-InflammamiR Axis in Metabolic Aging: From Diagnostic Clusters to Integrated Risk Phenotypes.Biomolecules · 2026Review
- Identifying risk individuals for heart failure diagnosis within two years in the adult population in southern Sweden using gender, age, multimorbidity level, and socioeconomic status.BMC cardiovascular disorders · 2026Article
- Review
- Risk factors for diuretic resistance in hospitalized patients with acute decompensated heart failure: a retrospective study.BMC cardiovascular disorders · 2026Article
- Phenotype-Specific Heterogeneity in Acute Kidney Injury, Dialysis, and Mortality Among Hospitalized Patients with Chronic Kidney Disease: A National Retrospective Cross-Sectional Study.Journal of clinical medicine · 2026Article
- Impact of chronic kidney disease stage on seizure frequency and severity in pediatric epilepsy patients.BMC nephrology · 2026Article
- Cardio-Vasculo-Renal Benefits of SGLT2 Inhibitors in Heart Failure: A Retrospective Study from a Lower-Resource Tertiary Center.Medicina (Kaunas, Lithuania) · 2026Article
- Anthracycline-induced cardiorenal toxicity: from molecular mechanisms to clinical management.Frontiers in cardiovascular medicine · 2026Review
- Association of estimated glomerular filtration rate and in-hospital mortality in patients hospitalized for heart failure: a retrospective cohort study.Frontiers in cardiovascular medicine · 2026Article
- Prevalence and clinical correlates of diabetes in hospitalized heart failure patients: a retrospective study.Frontiers in endocrinology · 2026Article
- Shen Shuai II Recipe alleviates renal fibrosis in chronic kidney disease by improving of hypoxia and inhibition of TLR4/MyD88/NF-κB/NLRP3 pathway.Renal failure · 2025Article
- Association of neutrophil-to-lymphocyte ratio with the risk of kidney failure in critically ill patients with heart failure: a cohort study.BMC cardiovascular disorders · 2025Observational
- SGLT2 Inhibitors in the Management of Cardio-Renal-Metabolic Syndrome: A New Therapeutic Era.Medicina (Kaunas, Lithuania) · 2025Review
- Early Administration of N-Acetylcysteine Provides Renal and Cardiac Mitochondrial and Redox Protection, Preventing the Development of Cardio-Renal Syndrome Type IV Induced by 5/6NX.Antioxidants (Basel, Switzerland) · 2025Article
- From Plants to Protection: Cardiorenal Benefits in Non-Diabetic Chronic Kidney Disease and Heart Failure.Molecules (Basel, Switzerland) · 2025Review
- Model for End-Stage Liver Disease Excluding INR Is Associated with Poor Prognosis in Elderly Patients with Decompensated Heart Failure.Biomedicines · 2025Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) is one of the greatest problems in healthcare and it often coexists with declining renal function. The pathophysiology between the heart and the kidneys is bidirectional. Common mechanisms leading to the dysfunction of these organs result in a vicious cycle of cardiorenal deterioration. It is also associated with difficulties in the treatment of aggravating HF and chronic kidney disease (CKD) and, as a consequence, recurrent hospitalizations and death. As the worsening of renal function has an undeniably negative impact on the outcomes in patients with HF, searching for new treatment strategies and identification of biomarkers is necessary. This review is focused on the pathomechanisms in chronic kidney disease in patients with HF and therapeutic strategies for co-existing CKD and HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.